Status Complete
Process STA
Referral date June 2015

Email enquiries


Key events during the development of the guidance:

Date Update
27 July 2016 Guidance published
17 June 2016 - 01 July 2016 Final appraisal determination
01 July 2016 Expected publication
19 April 2016 Committee meeting: 1
09 November 2015 Invitation to participate
August 2015

Following the CHMP positive opinion, the company met with the NICE team and proposed that the three scopes for nivolumab monotherapy (ID845, ID846 and ID847) could be combined into one Single Technology Appraisal (STA), with a second STA for nivolumab in combination with ipilimumab (ID848) to follow in line with the proposed license extension.

At the Decision Point 4 meeting, following the draft scope consultation and scoping workshop this approach was agreed

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance